Why Is North America Leading the Pulmonary Arterial Hypertension Market?
North America holds a dominant position in the global pulmonary arterial hypertension (PAH) market, commanding a 44.5% share in 2025. The region's leadership is built on advanced healthcare infrastructure, expert-centre density, and favorable reimbursement policies. Understanding the factors behind this dominance provides valuable insights into the dynamics shaping the Pulmonary Arterial Hypertension Market worldwide.
Advanced Healthcare Infrastructure and Expert Centres
The United States is the primary driver of the North American market. It has over 90 accredited comprehensive care centres for PAH, providing specialized diagnosis and treatment. The country's sophisticated healthcare system, with specialty pharmacy infrastructure and cold-chain capabilities, ensures that patients receive advanced therapies. The presence of major players, including United Therapeutics, Johnson & Johnson, and Merck & Co., means the region is a hub for PAH research and development.
Regulatory Support and Reimbursement
Canada also plays a significant role, with its universal healthcare system providing broad access to PAH treatments. The region's regulatory framework, overseen by the FDA and Health Canada, supports the approval of novel therapies through expedited pathways. Favorable reimbursement policies, including Medicare Part B coverage of continuous infusion supplies, reduce financial barriers. This supportive environment drives market growth and innovation.
People Also Ask
Which region dominates the PAH market?
North America holds a leading share of 44.5% in 2025, driven by advanced healthcare infrastructure, expert-centre density, and favorable reimbursement policies.
What factors are driving growth in the North American PAH market?
Key drivers include high disease prevalence, advanced therapies, favorable reimbursement policies, and the presence of major pharmaceutical companies.
With its combination of high demand, technological leadership, and supportive healthcare policies, North America will remain a pivotal region in the PAH market for years to come.
Tags: #NorthAmericaHealthcare #PAH #PulmonaryHypertension #RareDiseases #PharmaceuticalMarket